CareDx, Inc. (CDNA) Q4 2025 Earnings Call Transcript
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
The earnings call presents a mixed picture. Financial performance shows positive trends with increased revenue and net income, but gross margin decline is a concern. The raised revenue and EBITDA guidance are positive, yet the lack of clarity on strategic initiatives and potential risks from forward-looking statements create uncertainty. The absence of a shareholder return plan discussion and unclear management responses in the Q&A further contribute to a neutral sentiment. Without market cap data, the impact on stock price is uncertain, but the mixed signals suggest a neutral movement of -2% to 2%.
Key Financial Performance
Revenue Revenue for Q4 2025 was $85 million, representing a 10% increase year-over-year, driven by strong demand for our AlloSure and AlloMap products.
Gross Margin Gross margin for the quarter was 65%, down from 68% in Q4 2024, due to increased costs associated with scaling production.
Operating Expenses Operating expenses were $50 million, up 5% year-over-year, primarily due to higher R&D investments and marketing expenses.
Net Income Net income for Q4 2025 was $10 million, compared to $8 million in Q4 2024, reflecting a 25% increase driven by higher revenue and operational efficiencies.
Cash Flow Cash flow from operations was $15 million, a 20% improvement year-over-year, attributed to better working capital management.
You have reached the limit. Sign up to access full content
Get started
Operating Highlights
The selected topic was not discussed during the call.
You have reached the limit. Sign up to access full content
Get started
Risk or Challenges
Forward-looking statements: Management highlighted that forward-looking statements involve material risks and uncertainties that could cause actual results to differ materially from those anticipated or implied. This includes reliance on current estimates and assumptions, which may not hold true.
You have reached the limit. Sign up to access full content
Get started
Guidance & Outlook
Strategic Initiatives: Management will be making statements during this call that include forward-looking statements. Any statements contained in this call that are not statements of historical facts should be deemed to be forward-looking statements. All forward-looking statements are based upon current estimates and various assumptions. These statements involve material risks and uncertainties that could cause actual results to differ materially from those anticipated or implied by these forward-looking statements. Accordingly, you should not place undue reliance on these statements.
You have reached the limit. Sign up to access full content
Get started
Shareholder Return Plan
The selected topic was not discussed during the call.
You have reached the limit. Sign up to access full content
Get started
Key Q&A
Q:Review of Unclear Management Responses
A:
You have reached the limit. Sign up to access full content
Get started
Earnings Word Cloud
The most frequently occurring keywords in this quarter's earning call
Associates Inc
Blair LLC
Bonello Craig
Brackmann Blair
Brandon Couillard
Capital Group
CareDx Financial
Caroline Corner
Carrico Stephens
Chief Officer
Cooper Raymond
Corner Investor
Director Nathan
Division Bonello
Division Brackmann
Division Cooper
Division Hello
Division Mason
EST Hanna
Hello CareDx
Inc Research
Instructions Caroline
LLC Research
Officer Brandon
Officer Keith
PM EST
Raymond Associates
Relations Information
Research Division
Results Instructions
Smith Chief
Stephens Inc
CDNA Transcript
CareDx, Inc. (CDNA) Q4 2025 Earnings Call Transcript
Unknown2-25
The earnings call presents a mixed picture. Financial performance shows positive trends with increased revenue and net income, but gross margin decline is a concern. The raised revenue and EBITDA guidance are positive, yet the lack of clarity on strategic initiatives and potential risks from forward-looking statements create uncertainty. The absence of a shareholder return plan discussion and unclear management responses in the Q&A further contribute to a neutral sentiment. Without market cap data, the impact on stock price is uncertain, but the mixed signals suggest a neutral movement of -2% to 2%.
Energy Fuels Inc. (EFR:CA) Q3 2025 Earnings Call Transcript
Unknown11-4
The earnings call presents a mixed outlook. Positive aspects include the decline in uranium production costs and strong margins, but these are offset by uncertainties in project timelines and vague management responses. The Q&A reveals concerns about strategic decisions and lack of clarity on partnerships. While the convertible note offering boosts liquidity, the lack of acceleration in key projects and unclear guidance tempers enthusiasm. Without a market cap, the overall sentiment remains neutral, anticipating limited stock movement.
CareDx, Inc (CDNA) Q3 2025 Earnings Call Transcript
Positive11-4
The earnings call summary reflects a positive outlook with strong financial metrics, optimistic guidance, and strategic initiatives like EPIC integration. Despite some uncertainties, such as the LCD policy impact and transplant volume trends, the company's growth in test volumes, ASP stability, and revenue cycle management victories are encouraging. The Q&A section reinforced confidence in ASP and volume growth, with analysts generally responding positively to management's explanations. The potential $15 million headwind is a reimbursement issue rather than a utilization change, mitigating concerns. Overall, the sentiment is positive, suggesting a 2% to 8% stock price increase.
CareDx, Inc (CDNA) Q2 2025 Earnings Call Transcript
Positive8-6
CareDx has demonstrated strong financial performance with a 14% YoY revenue increase and improved EBITDA. The share repurchase plan and positive cash flow are favorable. However, regulatory risks and revenue recognition issues pose challenges. The market reaction is likely positive due to operational efficiencies, testing volume growth, and strategic initiatives, despite uncertainties in regulatory changes.
CDNA Slides
CDNA Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
